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ABSTRACT: Plasma protein binding (PPB) can possibly alter the already variable pharmacokinetics of voriconazole. Voriconazole PPB
was determined only once, being 58%, according to equilibrium dialysis (ED). We investigated voriconazole PPB more in detail, with
a convenient and newer high-throughput ED assay (HT-ED), in human blank plasma spiked with voriconazole and in plasma from
intensive care unit (ICU) patients treated with voriconazole. HT-ED was conducted in a 96-well plate, setup against phosphate-buffered
saline. Voriconazole concentrations were measured by liquid chromatography–tandem mass spectrometry. The median PPB was 47.6%
[interquartile range (IQR) 45.3%–50%] in vitro, and 49.6% (IQR 42.5%–52.5%) in ICU samples (p = 0.35), and is not depending on
total voriconazole concentration (0.7–11.2 mg/L, p = 0.65). The drug mainly binds to albumin (25.5 ± 5.1%), and to a lesser extent to
-1-acid glycoprotein (AAG; 4.8 ± 1.2%). The HT-ED assay can be performed at 37◦C or 25◦C (p = 0.44) and in batch: PPB variations
during freeze–thaw cycles (p = 0.13) and during frozen storage up to 12 months (p = 0.10) were not clinically relevant. Voriconazole
PPB is approximately 50%, according to HT-ED. As albumin and AAG only account for approximately 30% of total voriconazole PPB,
other plasma components could influence PPB and therefore efficacy or toxicity because of variations in unbound fractions. C© 2014 Wiley
Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2565–2570, 2014
Keywords: voriconazole; pharmacokinetics; protein binding; unbound fraction; high-throughput technologies; equilibrium dialysis;
albumin; -1-acid-glycoprotein
INTRODUCTION
Since the launch of voriconazole, the first-line treatment for
invasive aspergillosis,1 its extreme inter- and intraindivid-
ual variability in exposure has been a challenge in setting
an adequate therapy regimen.2–11 Several factors influencing
voriconazole plasma concentrations have been identified over
the last few years, such as saturable metabolism by CYP2C19,
CYP2C9 and CYP3A4,11–13 CYP2C19 polymorphism,14,15 drug
accumulation in liver disease,16 influence of age on its
metabolism,9 coadministration with CYP2C19- and CYP3A4-
interacting comedication,9 i.v. to oral switch,9,12,17,18 and im-
pact of food,19,20 all resulting in large intra- and interpatient
variability. Plasma protein binding (PPB) of voriconazole has,
however, never been investigated as a factor causing varia-
tions in voriconazole plasma concentrations. Yet, this would be
interesting, as only unbound drug concentrations exert phar-
macological activity. For drugs with linear pharmacokinetics,
hypoalbuminemia only seems to have relevant clinical impli-
Correspondence to: Kim Vanstraelen (Telephone: +32-16-34-23-39; Fax: +32-
16-34-30-84; E-mail: Kim vanstraelen@hotmail.com)
Journal of Pharmaceutical Sciences, Vol. 103, 2565–2570 (2014)
C© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association
cations in case of high protein binding (>70%).21 However, in
drugs with nonlinear pharmacokinetics, such as voriconazole,
an effect can probably be seen also for drugs with lower PPB,
because elevated unbound concentrations, resulting from hy-
poalbuminemia, cannot be eliminated immediately because of
saturated hepatic metabolism.
A first step in exploring the influence of hypoalbuminemia on
voriconazole protein-binding characteristics is the development
of a robust, reliable, and easy-to-use method for determining
voriconazole-unbound and voriconazole-bound concentrations.
Moreover, in vitro tests are needed to determine voriconazole
PPB in a reliable manner, enabling us to reveal alterations
in voriconazole PPB because of hypoalbuminemia in a future
project.
The most commonmethods for investigating protein binding
of drugs in vitro include equilibrium dialysis (ED), ultracen-
trifugation, and ultrafiltration.22–25 ED is the method of choice
in research settings, using a semipermeable membrane to sep-
arate unbound and bound fractions with subsequent analysis
of drug concentrations.22–25 It is typically considered to be the
gold standard, minimizing nonspecific binding of compounds to
the device and avoiding the need for large plasma volumes.24,26
Voriconazole PPB was previously reported to be 58%, according
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to ED results in premarketing studies, using a Dianorm Di-
alyzer (Harvard Bioscience Inc., Holliston, Massachusetts).27
No data are available about the impact of technical factors
potentially influencing PPB of voriconazole, such as temper-
ature during ED, mass balance, volume shift, freeze–thaw cy-
cles, and frozen storage. Nowadays, newer high-throughput ED
(HT-ED) assays are available28,29 (such as HTDialysis, Gales
Ferry, Connecticut; ThermoFisher Scientific, Waltham, Mas-
sachusetts; Spectrum Laboratories, Laguna Hills, California)
that are more user-friendly and more accurate compared with
former ED devices, because of even less nonspecific binding to
perform ED.24,29 HT-ED also allows minimal volume sampling
in a clinical patient setting.24,29
In this study, a robust and easy-to-use HT-ED assay is tested
for the determination of voriconazole PPB. Moreover, the influ-
ence of several technical factors during HT-ED on PPB charac-
teristics of voriconazole was investigated more in detail, both
in vitro as in vivo.
MATERIALS AND METHODS
Chemicals and Solutions
Voriconazole (0.35 kDa) was provided by Pfizer (New York) and
was used to prepare a stock solution of 3493 mg/L in methanol
(LC–MS grade from Acros Organics, Geel, Belgium). This stock
solution was further diluted in phosphate-buffered saline (PBS,
0.01 M phosphate buffer, 0.0027 M KCl, and 0.137 M NaCl, pH
7.4) to the appropriate concentrations for the different experi-
ments. "-1-acid glycoprotein (AAG) from Sigma–Aldrich BVBA
(Diegem, Belgium) was used to prepare PBS solutions of 1 g/L.
Albumin solutions were prepared in PBS, at a concentration
of 40 g/L, with AlbunormR© (Octapharma, Benelux, Belgium),
Albumin R© 20% (CAF, Brussels, Belgium), and Flexbumin R©
200 g/L (Baxter, Braine-l′Alleud, Belgium). All solutions were
freshly prepared at the moment of the experiments.
HPLC-graded water was generated using a Milli-Q-
water-purification system (Merck Millipore, Billerica, Mas-
sachusetts). Ethanol was bought from Prolabo VWR (Amster-
dam, The Netherlands). Pooled blank lithium heparin plasma
was collected from healthy volunteers. Samples from intensive
care unit (ICU) patients, treated with voriconazole for at least 4
days, were collected into lithium heparin tubes without gel sep-
arator, after approval by the local Ethical Committee and sign-
ing of the informed consent form. After centrifugation (10 min,
1500g), plasma was stored at −20◦C until further analysis.
HT-ED Followed by Liquid Chromatography-Tandem Mass
Spectrometry
Procedure
High-throughput ED was performed using a Teflon 96-well
ED device and dialysis membranes (molecular weight cut-off
12–14 kDa) from HTDialysis (model HTD96b). Prior to use,
the dialysis membranes were soaked for 60 min in 100% PBS,
followed by 20 min in PBS with 20% ethanol. Before placing
the membranes in the ED device, membranes were rinsed thor-
oughly with Milli-Q water so that they could be separated. In
each well, 150 :L PBS buffer was loaded in the dialysate side
against 150 :L investigational solution at the other side of
the semipermeable membrane, through which only unbound
molecules diffuse until equilibrium. Equilibration was carried
out during shaker incubation (150 rpm) (model EdmundBu¨hler
GmbH; type KS-15 control; Glasatelier Saillart, Meerhout, Bel-
gium) at 37◦C (Edmund Bu¨hler GmbH; TH15; Glasatelier Sail-
lart), whereas the device was covered with an adhesive seal-
ing film (HTDialysis), preventing evaporation of carbon diox-
ide (CO2) and pH changes. After reaching the equilibrium, so-
lutions from both compartments were stored at −20◦C until
analysis.
Determination of unbound and bound voriconazole concen-
trations was carried out using a previously in-house developed
and validated liquid chromatography–tandem mass spectrom-
etry (LC–MS/MS) method, with a LLOQ of 0.2 mg/L, between-
run precision, expressed as coefficient of variation, below 12%
and accuracy, expressed as a percentage of the theoretically
added concentration, between 89% and 109%. Linearity was
demonstrated from 0.06 to 20.0 mg/L.30
Calculation of PPB of Voriconazole
The percentage of unbound voriconazole was calculated using
the following formula22:
UF% =
[
voriconazole
]
PBS[
voriconazole
]
plasma
× 100
in which UF% stands for the percentage of unbound voricona-
zole. [Voriconazole]PBS and [voriconazole]plasma represent the
concentration of voriconazole at equilibrium, in the buffer com-
partment and plasma compartment, respectively.
Factors Influencing PPB During HT-ED
Time to equilibrium was determined using human blank
plasma, spiked with voriconazole at three clinically relevant
concentrations (1.75, 3.5, and 14 mg/L). Voriconazole concen-
trations and unbound fractions were determined after 1, 2, 4,
and 6 h of equilibration.
Mass balance was checked to rule out nonspecific adsorption
of voriconazole to the device, by comparing a total voriconazole
concentration of 3.4 mg/L in the plasma samples before HT-
ED and the sum of the recovered voriconazole amounts in the
buffer and plasma compartment after HT-ED.
All the latter in vitro tests were conducted using human
blank plasma spiked with different concentrations of voricona-
zole (0.7–1.4–2.8–5.6–11.2 mg/L). The influence of temperature
on PPB was investigated by conducting the HT-ED at 25◦C and
at 37◦C. Variations in PPB of voriconazole because of frozen
storage at −20◦C were investigated up to 12 months. The in-
fluence of 1–3–5 freeze–thaw cycles on PPB was also investi-
gated and the pH during ED, during frozen storage, and during
freeze–thawing was measured with a pH meter, model Consort
C830 (Consort BVBA, Turnhout, Belgium).
For every experiment, including time to equilibrium, HT-ED
analyses were conducted at least in triplicate. Except when in-
vestigating the influence of temperature on ED, all experiments
were performed at 37◦C.
Voriconazole PPB determined in blank plasma spiked with
voriconazole was compared with the PPB measured in plasma
from critically ill patients treated with voriconazole.
In Vitro-Binding Characteristics of Voriconazole
Binding characteristics of voriconazole to albumin and AAG
were investigated at 37◦C in PBS solutions with 40 g/L albumin
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Figure 1. Time to equilibrium (h) for a total voriconazole concentration of 1.7 mg/L (a), 3.5 mg/L (b), and 14 mg/L (c) in human blank plasma.
ED was performed at 37◦C during shaker incubation. Unbound and bound voriconazole concentrations were determined in triplicate for each
time point with the HT-ED device followed by LC–MS/MS.30 Based on the graph combined with the p values, equilibrium time (arrow) was set
at 2 h (a and c), and 4 h (b). *Significant difference.
(Albumin R© 20% 10 mL; CAF), 1 g/L AAG (Sigma–Aldrich
BVBA) or both, spiked with a fixed voriconazole concentration
of 3.5 mg/L.
The potential differences in PPB of voriconazole associated
with different commercial brands of human albumin were eval-
uated at 37◦C by adding voriconazole (3.5 mg/L) to 40 g/L al-
bumin in PBS, using AlbunormR© (Octapharma), AlbuminR© 20%
(CAF), and FlexbuminR© 200 g/L (Baxter).
Statistical Analysis
Statistical analysis was performed using SPSS 20.0 for Win-
dows (SPSS Inc. 2011, Chicago, Illinois). Depending on the
distribution of data, median, and interquartile range (IQR)
or mean and SD were calculated and the appropriate tests
were used (unpaired t-test or Mann–Whitney U test; one-
way ANOVA with post-hoc Tukey analysis or Kruskal Wallis
test, repeated measures ANOVA test, Linear Mixed Models,
or Friedman’s test; Regression Analysis). p < 0.05 was consid-
ered significant. The Bonferoni correction was used asmultiple-
comparison correction.
RESULTS
Equilibrium dialysis at 37◦Cduring shaker incubation revealed
an equilibration time of 2 h with 1.7 and 14 mg/L and 4 h,
with 3.5 mg/L total voriconazole concentrations (Fig. 1). On the
basis of these results, an equilibrium time of 4 h was applied in
all following experiments. Mass balance was confirmed, using
an initial voriconazole concentration of 3.4 mg/L: the sum of
voriconazole concentration in buffer and plasma compartment
after 4 h of equilibrium at 37◦C was 3.3 ± 0.007 mg/L, which is
within themargins of the analytical variance of the LC–MS/MS
method [95% confidence interval (3.2 mg/L; 3.6 mg/L)].
Plasma protein binding did not vary with different voricona-
zole concentrations at 37◦C (p = 0.65) (Table 1) and PPB was
not influenced significantly when HT-ED was performed at
25◦C versus 37◦C (p = 0.44), nor during 1–3–5 freeze–thaw cy-
cles, irrespective of total voriconazole concentration (p = 0.13)
(Fig. 2a). No clinically significant changes in PPB were seen
during the period of frozen storage (p = 0.10; data not shown).
The sum of voriconazole concentration in PBS and in plasma
remained stable overtime and did not differ from the concen-
trations of freshly prepared voriconazole in plasma solutions
up to 1 year of frozen storage (p = 0.96), indicating the stability
of voriconazole in both fluids.
pH increased during ED at 37◦C, from 7.38 (freshly prepared
plasma) to 7.68 (HT-ED during 6 h), with a mean difference of
0.26 ± 0.032 pH units compared with 7.38 (p < 0.001). An
increasing trend, with 0.0006 units per day (p < 0.001) was
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Table 1. Voriconazole (VRC) plasma protein binding (PPB) determined with HT-ED at 37◦C during 4 h with human blank plasma spiked
with different total VRC concentrations (mg/L)
PPB (Mean ± SD) Total VRC concentration (mg/L) spiked in human blank plasma p value
0.7 1.4 2.8 5.6 11.2
41.8 ± 5.3% 42.3 ± 5.9% 45.8 ± 2.0% 43.4 ± 1.0% 44.8 ± 0.8% 0.65
Figure 2. (a) Variation in plasma protein binding (PPB) of voriconazole during frozen storage up to 12 months. At each time point, PPB was
determined in triplicate for five different total voriconazole concentrations in human blank plasma. (b) Variation in pH value of human blank
plasma during frozen storage up to 12 months. Mean pH increased from 7.54 to 7.80.
also seen in pH values during frozen storage, ranging from
7.54 in freshly spiked plasma to 7.80 after 12 months of storage
(Fig. 2b).
In the in vitro experiment with albumin and AAG concen-
trations in PBS solution, voriconazole binds to albumin only
for 25.5 ± 5.1% and to AAG for 4.8 ± 1.2%. No clear differ-
ence was seen in PPB when using AlbunormR© 200 g/L (Oc-
tapharma), Albumine R© 20% 10 mL (CAF), and Flexbumin R©
200 g/L (Baxter) (33.4 ± 9.3%; 30.1 4.1%; 25.8 ± 5.4%, respec-
tively; p = 0.23).
Finally, the median (IQR) PPB of all in vitro experiments
with blank plasma spiked with voriconazole (N = 235) was
47.6% (45.3%–50%), which did not differ significantly (p= 0.35)
from the median PPB in 20 plasma samples from 13 ICU pa-
tients [49.6% IQR 42.5%–52.5%)]. Median albumin and AAG
concentrations in plasma of the ICU patients were 31.1 g/L
(IQR 28.4–33.2 g/L) and 1.8 g/L (1.5–2.2 g/L), respectively.
No exogenous albumin was administered within 1 month be-
fore sampling. The median total bilirubin plasma concentra-
tions was 0.41 (IQR 0.28–1.69 mg/dL). The median number of
voriconazole treatment days was 6 (IQR 4–14) and the me-
dian total voriconazole plasma concentration was 2.4 mg/L
(IQR 1.5–4.5).
DISCUSSION
We have tested an easily workable HT-ED assay for determi-
nation of the PPB of voriconazole. To our knowledge, this is
the first time that voriconazole PPB characteristics are investi-
gated thoroughly, with a robust method, excluding factors that
significantly influence the in vitro performance of the HT-ED
assay. We found that voriconazole PPB could be determined
accurately and robustly using HT-ED without significant in-
fluence of several factors such as environmental temperature
(p = 0.44), freeze–thaw cycles (p = 0.13), and duration of frozen
storage at −20◦C up to 12 months (p = 0.10).31
Moreover, the Teflon material of the 96-well plate prevents
nonspecific adsorption of drug, as illustrated by the mass
balance experiment.28 Volume shift, because of osmotic pres-
sure, is minimal because equilibrium is already reached within
4 h.23,32 Because the stock solutions in methanol were first di-
luted in PBS buffer, the amount of solvent in the ED device was
minimized to 0.02%–0.32%, preventing influence from solvent
addition on the protein-binding equilibrium.23,33
In all experiments, voriconazole PPB was independent of to-
tal voriconazole concentration, ranging from 0.7 to 14 mg/L.
Although the reference range of plasma voriconazole concen-
trations is set at 1 or 2–5.5 mg/L, often subtherapeutic (below
1 mg/L) and supratherapeutic (above 5.5 mg/L) plasma con-
centrations are seen in patients treated with voriconazole.4,34
Because of the nonlinear pharmacokinetics, even plasma con-
centrations of 10–20 mg/L can be measured in some patients.
This concentration independency can partly be explained be-
cause normal therapeutic voriconazole plasma concentrations
(1 or 2–5.5 mg/L4,34) are many times smaller than the average
plasma albumin concentration (±35–50 g/L),35 implying non-
saturated albumin binding.
The fluctuations in pH during ED and during frozen storage
seen in this project are most likely irrelevant, although it is
often suggested that they occur because of CO2 evaporation,36
possibly inducing conformational changes to plasma proteins,
resulting in an altered binding profile.37,38 However, albumin
conformational change only occurs at pH above 8.37 A change
in degree of ionization of voriconazole because of pH changes
is also not applicable, because voriconazole behaves as a weak
base with a pKa value of 1.76.39 The variations in PPB during
frozen storage for different total voriconazole concentrations
are most likely not relevant in clinical practice, because they
are all fluctuating around 50%.
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Themedian PPB, both in blank plasma spikedwith voricona-
zole [47.6% (IQR 45.3%–50%)] as in plasma from ICU patients
treated with voriconazole [49.6% (42.5%–52.5%)] differed from
58%, as determined several years ago in the premarketing
study.27 Despite the fact that these differences in PPBmight not
lead to major changes in pharmacokinetics insights of voricona-
zole, we believe that the difference should primarily be evalu-
ated from a technical point of view and that our reported PPB is
more accurate because of an improvement of the study design.27
First, and most importantly, the median in vitro PPB in our
study was the result of 235 measurements, and was for the
first time in literature, confirmed in plasma coming from 13
ICU patients treated with voriconazole. In the premarketing
study,27 time to equilibrium was set at 2 h, based on only one
experiment with human plasma spiked with one concentration
of voriconazole (i.e., 1 mg/L) in triplicate, which differs from our
experiment where time to equilibriumwas determined to be 4 h
at several different clinically relevant voriconazole concentra-
tions. Second, the DianormDialyzer was rotated at 15 rpm dur-
ing equilibration, compared with shaker incubation at 150 rpm
in our experiment, which could have influenced time to equi-
librium. Differences in thickness and pore diameter of the
membranes used in the Dianorm Dialyzer compared with our
assay could have influenced the diffusion of unbound voricona-
zole molecules and therefore time to equilibrium. Roffey et al.27
used a volume of 1 mL plasma and buffer, compared with only
150 :L at both sides of the membrane in the HT-ED device.
Third, in the premarketing study, a 0.1M phosphate buffer was
used, which can possibly cause more volume shift because of a
higher osmolarity comparedwith the PBS solutionwith 0.012M
phosphate used in the HT-ED device. Volume shift can alter the
results, because in the calculations as mentioned in the Mate-
rials and Methods section of our manuscript, an equal volume
in both compartments is assumed.
Fourth, as liquid scintillation counting, which is the ana-
lytical method used by Roffey et al.,27 is more prone to mea-
surement variations, it might have resulted in lower precision
and accuracy compared with our LC–MS/MS method,30 pos-
sibly explaining in part the differences in protein binding of
voriconazole between the two assays.
It is not completely clear whether these differences could
have influenced the results; on the contrary, they cannot be
neglected.
No information about mass balance is available for the Di-
anorm Dialyzer method.
To our knowledge, this is also the first study investigating
which plasma components could be responsible for the total
PPB of voriconazole. According to our results, albumin seems
to be the main contributor to voriconazole PPB, although in lit-
erature, basic drugs have shown to bind preferably to AAG.40
However, because only a PPB of approximately 30% was ob-
served in vitro when combining clinically relevant concentra-
tions of albumin and AAG, we believe that other components
in human plasma are involved in voriconazole PPB, such as
lipoproteins and "-, $-, (-globulins.23,40–43 The clinical relevance
of these observations should be further explored.
As albumin was found to be the predominant protein de-
termining voriconazole PPB, we were interested in evaluat-
ing the potential differences in binding capacities of albumin
from different commercial brands. The impact of the presence
of different stabilizers and suppliers has been a matter of de-
bate before.44 On the basis of our results, voriconazole PPB
remained stable in vitro, irrespective of the commercial brand
of albumin (p = 0.23). Furthermore, the method described in
this manuscript can be used in future clinical studies inves-
tigating our hypothesis about the influence of hypoalbumine-
mia on voriconazole protein-binding characteristics, despite its
moderate protein binding.
The disadvantages of HT-ED, being its time-consuming na-
ture (±2 h of preparation and 4 h of equilibration) and the
costs of the device, do not outweigh the advantages such as the
possibility of batch analysis, the easy assembly, use and clean-
ing, the compatibility with multichannel equipment, and most
important, the possibility of automatization.28,29
CONCLUSION
Voriconazole protein binding is approximately 50% in human
plasma, according to an accurate, easy usable HT-ED method.
As albumin is the main contributor to voriconazole PPB, this
HT-ED-based method can be used in future studies to elucidate
the influence of hypoalbuminemia on voriconazole pharmacoki-
netics and its relevance in clinical practice.
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